Apthera has assembled a strong intellectual property (IP) position from renowned institutions to serve as the foundation of the company. Due to this strong IP position held by Apthera, there is limited, direct competition in the HER2/neu peptide field and our lead indications. Apthera’s products are unique to the market in our treatment approach, mechanism of action, and late stage of product development.

Currently, the patent portfolio consists of:

• MDA 94-022, entitled "Cancer Therapies by HER-2 Peptides," and U. S. Patent No. 6,514,942, created by Constantin G. Ioannides, Bryan A. Fisk and Maria Ioannides.
• MDA 01-049, entitled "Induction of Tumor Immunity by Controlled Modification of Amino Acid Side Chain Length Using Methyl/Methylene (CH2/CH3)," and U. S. Provisional Application No. 60/362,778, created by Constantin G. Ioannides, Martin L. Campbell, Catherine O. O’Brian and George Peoples.

Apthera will continue to generate its own intellectual property and trade secrets using its novel screening and discovery systems as well as its peptide modification technology licensed from our clinical trial center, and may license additional peptide-based technology on an opportunistic and/or strategic basis.